Aura Biosciences Announces Board and Executive Changes
Ticker: AURA · Form: 8-K · Filed: 2024-04-15T00:00:00.000Z
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
Related Tickers: AURA
TL;DR
Aura Bio (AURA) board shakeup and exec comp changes announced April 12.
AI Summary
Aura Biosciences, Inc. announced on April 12, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: medium — Board and executive changes can indicate internal shifts that may affect future performance or strategy.
Key Players & Entities
- Aura Biosciences, Inc. (company) — Registrant
- 001-40971 (company) — SEC File Number
- 32-0271970 (company) — I.R.S. Employer Identification No.
- 80 Guest Street Boston, MA 02135 (company) — Business Address
- (617) 500-8864 (company) — Business Phone
FAQ
What specific roles have seen departures or appointments?
The filing indicates departures of certain officers and directors, and the election of new directors, but does not specify the exact roles in this summary.
When were these changes effective?
The earliest event reported is dated April 12, 2024.
What is Aura Biosciences, Inc.'s primary business?
Aura Biosciences, Inc. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
Where is Aura Biosciences, Inc. headquartered?
The company's principal executive offices are located at 80 Guest Street, Boston, MA 02135.
What type of SEC filing is this?
This is a Form 8-K, a Current Report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-04-15 16:07:56
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share AURA The Nasdaq
Filing Documents
- d786960d8k.htm (8-K) — 22KB
- 0001193125-24-096204.txt ( ) — 141KB
- aura-20240412.xsd (EX-101.SCH) — 3KB
- aura-20240412_lab.xml (EX-101.LAB) — 18KB
- aura-20240412_pre.xml (EX-101.PRE) — 11KB
- d786960d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 15, 2024 AURA BIOSCIENCES, INC. By: /s/ Julie Feder Julie Feder Chief Financial Officer